Fudan University Shanghai Cancer Center (FUSCC)
Fudan University Shanghai Cancer Center (FUSCC) — Shanghai
Hospital Profile
Fudan University Affiliated Tumor Hospital was established on March 1, 1931. It is the earliest tertiary A-level specialized tumor hospital in China that integrates medical care, education, research, and prevention. It is jointly managed by the Ministry of Education, the National Health Commission, and the Shanghai Municipal People's Government. In the "China Best Hospital Comprehensive Rankings," it ranks 25th nationwide; its Pathology Department has been ranked first in the country for nine consecutive years, Oncology ranks second nationwide, and Thoracic Surgery ranks tenth nationwide. For six major diseases—thyroid cancer, breast cancer, colorectal cancer, pancreatic cancer, prostate cancer, and ovarian cancer—the hospital’s performance data ranks first in the city. The hospital has an academic workstation for Academician Wang Hongyang and multiple PhD/Master supervisors. In 2019, the amount of research funding exceeded 100 million yuan, with 87 projects funded by the National Natural Science Foundation, one project under the Ministry of Science and Technology's "Major New Drug Development" initiative, and multiple provincial and ministerial-level science and technology awards.
Medical Milestones
Founded in 1931; on May 8, 2015, Shanghai Proton and Heavy Ion Hospital (Proton and Heavy Ion Center of Fudan University Cancer Hospital) began operation; on August 23, 2019, the Pudong campus opened, initiating a new model of multidisciplinary comprehensive tumor treatment (MDT) and single-disease diagnosis and treatment; first in the country to use facial recognition technology to manage expert appointment sources; established the cancer prevention and treatment medical consortium in East China and the Yangtze River Delta region.
Key Capabilities & Patient Care
There are 26 clinical and medical technology departments, forming a 'one body, two wings' pattern (Xuhui Campus, Pudong Campus, and highly integrated with Shanghai Proton and Heavy Ion Hospital). The average length of stay for discharged patients is only 4.9 days, with operational efficiency leading nationwide. It has 2 key disciplines designated by the Ministry of Education (Oncology, Pathology), 3 national clinical key specialties, and 3 key clinical disciplines of the Ministry of Health. Information technology is used to promote cancer prevention, screening, and full-cycle patient care. It actively carries out paired assistance (Morocco, Tibet, Xinjiang, Yunnan, etc.) and advances the construction plan of the telemedicine system.
Advanced Technology
Integrating surgical operations, chemotherapy, photon radiotherapy, and proton-heavier ion therapy technologies, the Proton and Heavy Ion Center carries out advanced treatments for nasopharyngeal carcinoma, intracranial and skull base tumors, early-stage lung cancer, liver cancer, prostate cancer, and pancreatic cancer (the '5+1' key diseases), having treated more than 2,500 cases. It hosts multiple provincial-level/Fudan University research platforms, including the National Drug Clinical Trial Institution, Shanghai Key Laboratory of Breast Tumor, Shanghai Clinical Medical Research Center for Pathological Diagnosis, and Precision Oncology Center. It also founded four academic journals, including the Chinese Journal of Cancer and the English version, Precision Cancer Medicine, as well as the popular science magazine Anti-Cancer. Data statistics: • Bed capacity: Over 2,000 actual open beds • Total staff: 2,561 faculty and staff (655 physicians, 1,182 nurses, 520 medical technicians; 345 senior and associate senior experts; 63 doctoral supervisors, 96 master's supervisors) • Inpatient volume: 163,800 hospitalizations in 2023 (forecast for 2025) • Outpatient and emergency volume: 2,021,600 visits in 2023 (forecast for 2025) • Inpatient and elective surgeries: 78,900 surgeries in 2023 (forecast for 2025); 174,000 chemotherapy treatments, 18,400 radiotherapy treatments in 2023; over 2,000 ovarian cancer surgeries in 2024 (accounting for 45% in Shanghai), nearly 3,000 pancreatic cancer surgeries per year • Number of physicians with senior professional titles: 345 senior and associate senior experts
International Patient Services
Signed framework agreements with 11 top international institutions, including the Anderson Cancer Center in Texas, USA, Gustave-Roussy Cancer Center in France, Princess Margaret Cancer Centre in Canada, and the Cancer Science Centre at the University of Nottingham in the UK, to carry out in-depth cooperation in medical care, scientific research, talent training, and international patient referrals. (No specific services of an independent special needs department/international department were mentioned)